Nicox: 2020 Extraordinary General Meeting postponed to June 30, 2020

June 15, 2020
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, informs its shareholders that the extraordinary general meeting convened on first call on June 16, 2020, cannot be held as the quorum required by law will not be reached.

The shareholders are thus convened on second call for an extraordinary general meeting on the same agenda on Tuesday June 30, 2020 at 2:00 pm CET in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.

The documents mentioned in articles R.225-73-1 of the French Code de commerce, including those to be presented at the general meeting, are available on the Company's website www.nicox.com. These documents are also available to shareholders at the headquarters of the Company.

Shareholders may vote by proxy, by internet or by attending the general meeting in person. A guide explaining how to vote is available on Nicox's website. Shareholders may also contact the Company's Investor Relations team at age2020nicox@nicox.com for any question on the voting process. The proxy forms sent for the first call remain valid. Shareholders having requested to attend the June 16, 2020 general meeting may attend the June 30, 2020 meeting.

About Nicox

Nicox S.A. is an ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch & Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumenion Therapeutics in the Chinese and Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

<table>
<thead>
<tr>
<th>Analyst Coverage</th>
<th>Contact Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryan, Gamier &amp; Co</td>
<td>Paris, France</td>
</tr>
<tr>
<td>Victor Floc’h</td>
<td>New York, U.S.</td>
</tr>
<tr>
<td>Cantor Fitzgerald</td>
<td>Louise Chen</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>New York, U.S.</td>
</tr>
<tr>
<td>H.C. Wainwright &amp; Co</td>
<td>Hartaj Singh</td>
</tr>
<tr>
<td>Oppenheimer &amp; Co</td>
<td>New York, U.S.</td>
</tr>
</tbody>
</table>

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer & Head of Corporate Development

www.nicox.com
Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox’s website (www.nicox.com).